Access cutting-edge infant leukemia treatment through this clinical trial at a research site in Anchorage. Study-provided care at no cost to qualified participants.
Access infant leukemia specialists in Anchorage at no cost
This study follows strict safety protocols and ethical guidelines
All study-related infant leukemia treatment provided free
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without a KMT2A gene rearrangement (KMT2A-germline \[G\]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoc
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this infant leukemia clinical trial in Anchorage, AK
If you're searching for infant leukemia treatment options in Anchorage, AK, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Anchorage research site is actively enrolling participants for this clinical trial. You'll receive care from experienced infant leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.